ReShape Lifesciences announces $1.5 million registered direct offering
ReShape Lifesciences announced it has entered into definitive agreements with several institutional investors for the purchase of 469,490 shares of its common stock, at a purchase price per share of $3.07, for gross proceeds of $1.44 million, in a registered direct offering priced at-the-market. June 20, 2018